Cryoport Systems with ISCT on Why Early-Phase Development is Starting to Strain 

As advanced therapy programs move faster toward first-in-human (FIH), the pressure isn’t just showing up at commercial scale. It’s appearing much earlier than many teams expect.  

A recent article Cryoport Systems published with ISCT takes a closer look at that shift, highlighting why execution (not feasibility) is increasingly becoming the constraint in early development. One of the dynamics it highlights is how early-phase teams are now being asked to operate with a level of operational rigor that hasn’t historically applied to that stage. Development timelines are compressing, regulatory engagement is happening sooner, and external expectations around readiness have moved upstream.  

The article points to a shift in how investors and regulators now evaluate early-stage programs. Where questions used to center around whether the science is compelling, today it’s becoming more focused on whether the workflows and supply chain supporting the program can scale without requiring significant rework.  

FIH studies are where many early decisions start to do real work. What felt flexible in preclinical development is tested in the real world against structured timelines and under greater scrutiny. Programs that planned for that transition tend to move more steadily, while others are finding themselves revisiting foundational choices right when speed becomes critical.  

Early infrastructure is no longer something teams can defer. It shapes how much flexibility a program retains as it grows.  

 

Read the full article here: 
Early-Phase Advanced Therapy Development is Breaking Under its Own Momentum

Category: Industry Insights
Topics: Commercialization, Global Supply Chain Management

What to read next

Cryoport Systems in Labiotech on Where CGT Supply Chains Start to Break
Industry Insights
05/26/2026

Cryoport Systems in Labiotech on Where CGT Supply Chains Start to Break

As more cell and gene therapy programs push toward later-stage trials and commercialization, a familiar set of pressures is starting to surface. What once felt manageable at smaller scale begins to take more effort to hold together as volumes pick up. A recent article in Labiotech, developed in collaboration with Cryoport Systems, looks closely at where that strain comes from and how it often traces back to decisions made much earlier in development.

Read More

Read More
Matthew Plaud on Building Supply Chains that Actually Scale
Industry Insights
05/26/2026

Matthew Plaud on Building Supply Chains that Actually Scale

In a recent conversation with Contract Pharma, Matthew Plaud, COO of IntegriCell® at Cryoport Systems, discussed where advanced therapy supply chains stand today, and where they start to strain as programs move toward commercialization.

Read More

Read More
Building Global Readiness: Key Takeaways from Matthew Frazzetta at Hope Is Not a Workflow
Industry Insights
04/14/2026

Building Global Readiness: Key Takeaways from Matthew Frazzetta at Hope Is Not a Workflow

As cell and gene therapies continue to advance scientifically, operational readiness is increasingly determining whether those therapies reach patients at scale. During a presentation at Hope Is Not a Workflow, Matthew Frazzetta, Vice President of Global Accounts for BioServices at Cryoport Systems, addressed a question that is becoming impossible for the industry to ignore: How do we build a global, standardized, and scalable supply chain capable of supporting the next generation of advanced therapies?

Read More

Read More